Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma.
G. Magalhães (Belo Horizonte , Brazil), J. Gregorio (Belo Horizonte , Brazil), G. Nakashima (Belo Horizonte , Brazil), A. Ribeiro (Belo Horizonte , Brazil), A. Oliveira (Belo Horizonte , Brazil), L. Barcelos (Belo Horizonte , Brazil), R. Santos (Belo Horizonte , Brazil), M. Campagnole-Santos (Belo Horizonte , Brazil), M. Rodrigues-Machado (Belo Horizonte , Brazil)
Source: International Congress 2019 – Modelling and monitoring of airway diseases
Session: Modelling and monitoring of airway diseases
Session type: Thematic Poster
Number: 4366
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Magalhães (Belo Horizonte , Brazil), J. Gregorio (Belo Horizonte , Brazil), G. Nakashima (Belo Horizonte , Brazil), A. Ribeiro (Belo Horizonte , Brazil), A. Oliveira (Belo Horizonte , Brazil), L. Barcelos (Belo Horizonte , Brazil), R. Santos (Belo Horizonte , Brazil), M. Campagnole-Santos (Belo Horizonte , Brazil), M. Rodrigues-Machado (Belo Horizonte , Brazil). Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma.. 4366
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Efficacy of UR-63325, a new H4 receptor antagonist, in two rodent asthma models Source: Annual Congress 2010 - Models of airways disease Year: 2010
Anti-asthmatic effects of losartan, a blocker of angiotensin II type 1 receptor, in a rat model of allergic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
Distinct effects of the endothelin receptor antagonists PD 142893 (ET-A/B), BQ 788 (ET-B) and N-Ac-Trp-ET 1 Frg. 16-21 (ET-A) on oxidative stress-induced pulmonary hypertension in isolated rabbit lungs Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001
Tachykinin 1 receptor antagonist FK888 suppresses angiotensin converting enzyme inhibitors (ACEIs)-induced tracheal inflammation, an experimental study Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
Nicotinic alpha-7 receptor stimulation (a7nAChR) inhibited NF-kB/STAT3/SOCS3 pathways in a murine model of asthma. Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017
Cystenyl-leukotriene receptor antagonist (LRA) inhibits respiratory burst of human neutrophils Source: Eur Respir J 2003; 22: Suppl. 45, 316s Year: 2003
CS-003, a novel triple neurokinin receptor antagonist, inhibits symptoms of respiratory diseases models in guinea pigs Source: Eur Respir J 2006; 28: Suppl. 50, 664s Year: 2006
The endocannabinoids anandamide and 2-arachidonyl-glycerol (2-AG) induce pulmonary hypertension (PH) in a CB1 receptor independent manner - role of COX-2 and EP1 receptor activation Source: Eur Respir J 2005; 26: Suppl. 49, 733s Year: 2005
A novel receptor antagonist, c-027, inhibits airway contraction in human and murine models of allergen, independent of inflammatory mediator release Source: Annual Congress 2009 - Novel mechanisms in the pathogenesis of asthma Year: 2009
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
A novel lung pharmacokinetic model predicts lung exposure and supports dose selection for clinical study of AZD2115, a dual muscarinic receptor antagonist/beta2 adrenoceptor agonist (MABA) Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015
An orally available, highly selective 5-hydroxytryptamine 2B (5-HT2B) receptor antagonist ameliorating pulmonary and dermal fibrosis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019
Selective versus non-selective endothelin receptor antagonists Source: Annual Congress 2005 - New treatments in pulmonary hypertension Year: 2005
The effect of leukotrienes and their receptor antagonists on calcium signalling in the cough receptors transient receptor potential ankyrin 1 (TRPA1) and vanilloid 1 (TRPV1) Source: Annual Congress 2010 - Models of airways disease Year: 2010
A potential new therapy for pulmonary hypertension with the use of compound 21, an angiotensin type 2 receptor (AT2R) agonist Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010
AZD1402/PRS-060, an inhaled Anticalin® IL-4Ra antagonist, potently inhibits IL-4 induced functional effects in human whole blood, which can be employed translationally in clinical studies. Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018
Effects of the novel toll-like receptor 7 (TLR7) agonist AZD8848 on allergen-induced responses in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Acupuncture regulates macrophage polarization in COPD mice model by activating dopamine D2 receptor. Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Protective effect of a protein epitope mimetic (PEM) CCR10 antagonist, POL7085, in an allergic model of asthma Source: Annual Congress 2011 - Translational models of airway disease Year: 2011